Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Insider information: Merus Power received a battery energy storage order of around 15 million from eNordic and Lappeenrannan Energia - The new battery energy storage system strengthens the power grid

Merus Power Plc, Insider information, Company release, 13 Feb 2024 at 19.00 pm Merus Power has signed a contract with a joint venture between Skip Wind 5 Oy, a Finnish holding company of Ardian Clean Energy Evergreen Fund (ACEEF), and Lappeenrannan Energia Oy, a Finnish municipal energy company, to supply a large battery energy storage system (BESS). This 38-megawatt and over 40-megawatt-hour energy storage system will support the Finnish power grid. The project is slated for completion by spring 2025 and will be located in Lappeenranta, near the Mertaniemi power plant. Merus Power’s

Invitation: Tecnotree to publish Financial Statement Release 2023 on February 22, 2024

Tecnotree Investor News February 13, 2023Tecnotree Oyj will publish its Financial Statement Release 2023 on Thursday, February 22, 2024 around 9.00 am (EET). In addition, Tecnotree will host a virtual result webcast for analysts, investors, and media on Thursday, February 22, 2024, starting at 1.00 pm (EET). At the event, Padma Ravichander, the CEO and Indiresh Vivekananda, the CFO will present Tecnotree’s results.The webcast, including a Q&A session, will be held in English. Participants will be able to ask questions in English on the webcast platform at:https://tecnotree.videosync.fi/

Kemira Oyj: Change in the composition of the Nomination Board

Kemira Oyj, Stock Exchange Release, February 13, 2024 at 6.30 pm (EET)Kemira Oyj: Change in the composition of the Nomination BoardOn February 13, 2024 Kemira announced that Solidium Oy had sold its holding in Kemira. Following the change in Solidium Oy’s ownership, Pauli Anttila, Solidium Oy’s Investment Director, has given up his position in Kemira Oyj’s Nomination Board today.   Until the composition of the  Nomination Board is updated based on the ownership situation on May 31, 2024, Kemira Oyj’s Nomination Board will continue with the following composition:  -

CEO and chairman present as construction of Enviro's plant officially kicked off

Enviro's CEO Fredrik Emilson, chairman Alf Blomqvist, and board member Peter Möller were present as the construction of Enviro Systems' recycling plant in Uddevalla officially began today. Together with Uddevalla's municipal councilor Martin Pettersson and the property owner Fratera's CEO Peter Karlsson, they held a symbolic groundbreaking ceremony with the assistance of an excavator. Alf Blomqvist, chairman Enviro, Peter Karlsson, CEO Fratera, Fredrik Emilson, CEO Enviro, Martin Pettersson, municipal councilor Uddevalla. Since Enviro, Antin Infrastructure Partners, and Michelin

Calliditas provides patent update

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the United States Patent and Trademark Office (USPTO) issued patent no. 11896719, entitled “New Pharmaceutical Compositions, on January 24, 2024 with validity as of today, February 13, 2024.  This is Calliditas’ second patent for TARPEYO in the United States, and provides product protection until 2043.The patent covers a method of treating IgA nephropathy with a composition that encompasses TARPEYO® (budesonide) delayed release capsules, developed under the name “NEFECON®”. Filing for

OKEA ASA - Purchases under share-based bonus program

Trondheim, 13 February 2024 Reference is made to the stock exchange announcement made 13 February 2024 regarding share purchase by DNB on behalf of 440 employees of OKEA ASA (the "Company", or "OKEA"). Today, a total of 150,000 shares in the Company were acquired in connection with the Company's share-based bonus program. The share purchases were executed collectively at an average purchase price of NOK 23.3146 per share.

Energy efficiency in focus: Teknos presents pioneering solutions at PaintExpo!

At this year's PaintExpo in Hall 2, Stand 2338, Teknos will be presenting pioneering coating solutions with a clear focus on energy efficiency, increased productivity, and cost efficiency. The stand will be a hotspot for innovative solutions that not only significantly increase the speed of production processes, but also help to reduce energy costs. With a holistic approach that puts customer needs first, Teknos is working with its customers to shape a more sustainable future. Visitors can expect more than just paint - see how Teknos is redefining the entire painting process and shaping the

Form 8.3 - Mondi Plc

FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   +----------------------------------------------------------+------------------+|(a) Full name of discloser: |Ninety One UK Ltd |+----------------------------------------------------------+------------------+|(b) Owner or controller of interests and short positions |  ||disclosed, if different from 1(a):

New paper using Attana Technology to study structures on surface in Ion Liquids demonstrating the effect of surface charges on interaction properties.

In the paper in "Journal of Colloid And Interface Science ", the Attana quartz crystal microbalance (QCM) is applied to study the electrical response of two ionic liquids. Controlled by an applied electric field, the structure and interaction of ionic liquids on the surface, can be monitored and optimized. This is of high importance for the development of e.g. environment friendly lubricants. This is the third paper by the team of Prof Rutland that demonstrates how Attana technology can be applied to monitor interaction

Save the date for the Alfa Laval Capital Markets Day on 21 November 2024

This year we will take the Capital Markets Day to southern Europe and visit our heat exchanger manufacturing site in San Bonifacio in Italy.The in-person event will include a site visit in one of Alfa Laval’s most advanced production facilities, as well as presentations from the CEO and other members of Group Management. The event will start in the morning of 21 November 2024 with a dinner the evening before. An invitation with further information and possibility to register to the event will be sent out closer to the event. For more information please contact:Johan LundinHead of

Observe Medical – First orders to the Irish Hospital Market

Oslo, February 13, 2024 - Observe Medical ("the Company" or "Observe Medical") has received first orders for delivery of UnoMeter™ 500 products from our distributor in Ireland, Armstrong Medical. We are set to dispatch 2,800 units of the UnoMeter™ 500 this week, with an additional 2,500 units scheduled for shipment by the end of February. The shipments are being facilitated via C&P Medical, our distributor based in the UK. This initial order places us well within the Urinemeter market in Ireland, which has an annual potential of approximately 15,000 units. Armstrong Medical will

Jouni Grönroos has decided to leave Fazer – Jukka Erlund appointed CFO for Fazer Group

Fazer Group’s CFO and Deputy CEO Jouni Grönroos has decided to leave Fazer. Jukka Erlund, M.Sc. (Econ), eMBA, (b. 1974) has been appointed as the company’s new Chief Financial Officer and member of the Fazer Leadership Team. He will assume his position in August at the latest.Jukka Erlund has worked at Kesko Corporation since 2004 and has been Executive Vice President, CFO in the company since 2011. Prior to this position, he served as Vice President for Finance in Kesko Food Ltd and has in addition also held several other major finance positions in the company during his career. Jukka

SRV’s change negotiations have been completed

SRV GROUP PLC                        STOCK EXCHANGE RELEASE                          13 FEBRUARY 2024 AT 15:00 EET  SRV’s change negotiations have been completed  SRV has today, Tuesday, completed change negotiations in accordance with the co-operation act. At the start of the negotiations, the company estimated that the need for permanent personnel reductions would be 35 person-years at most. The negotiations resulted in personnel reductions of a total of 19 person-years. In addition, 6 people will be laid off until further notice. As part of the negotiated solution, the company also

Change in Kesko’s Group Management Board

Kesko Corporation’s Chief Financial Officer Jukka Erlund has announced that he will be leaving Kesko and joining Fazer Group as Chief Financial Officer. Erlund has been Kesko’s CFO and a member of the Group Management Board since November 2011. Erlund will be leaving his current position by August 2024. Kesko has begun the process of finding a successor for Erlund. "Jukka Erlund has forged a long and successful career in Kesko since 2004. He has played a central role in Kesko’s growth, strategic transformation, and internationalisation. I want to express my warmest thanks to Jukka for

BiBB launches new website

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared motorized endoscopic core biopsy instrument, announces that the Company has launched a new website with a new design and content that better reflects BiBB’s umcoming commercialization journey.Following the recent successes with market clearances in the USA and Europe for the EndoDrill[®] system, patent approvals in Europe, and successful clinical introduction in the USA, BiBB is launching a new website. The website features new graphics and updated text that better

NRC Group ASA - Appointed to contract in Norway - NOK 78 million

Å Energi Vannkraft has appointed NRC Norge AS, a company wholly owned by NRC Group ASA, to a contract for the renovation of Dam Nespervatn.  The contract is valued at approximately NOK 78 million, and the work will commence in May 2024 and is scheduled for completion in December 2025.  For further information, please contact: Ole Gulsvik, CFO of NRC Group, + 47 99 56 85 20. This information is considered to be inside information pursuant to the EU Market Abuse Regulation, and is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading

Cereno Scientific announces new Executive Management Team

Cereno Scientific (Nasdaq First North: CRNO B) today announced that they have expanded the Executive Management Team to include the newly appointed Chief Medical Officer & Head of Research & Development, Rahul Agrawal, and the Business Development Director, Julia Fransson, to strengthen focus on the strategic priorities in development programs of lead candidate drug CS1 in PAH, and CS014 in thrombosis prevention and CS585 in not yet decided cardiovascular indication.The Executive Management Team now includes: · Chief Executive Officer (CEO) – Sten R. Sörensen · Chief Scientific

DOF Group ASA - CFO stepping down, Head of Investor Relations to take over

Hilde Drønen, CFO of DOF Group ASA, has decided to step down from her role by the end of 2024. Drønen has served the position as CFO since 2005. Martin Lundberg, SVP Finance and Head of Investor Relations, will be appointed as the new CFO for the Group and will work closely with Mrs. Drønen until the end of the year. CEO Mons S. Aase says: “I’ve been working together with Hilde for more than 25 years and I am thankful for her huge contribution and capacity through all these years. Hilde has provided the company with strong financial leadership and has been instrumental in

Cereno Scientific appoints Dr. Rahul Agrawal as Chief Medical Officer and Head of R&D

Cereno Scientific (Nasdaq First North: CRNO B) today announced that Dr. Rahul Agrawal has been appointed as Chief Medical Officer and Head of R&D. The recruitment follows an intense period in the clinical-stage biotech’s growth journey. Cereno is focused on developing innovative treatments for common and rare cardiovascular disease, with lead candidate drug CS1 currently in phase II for the orphan disease pulmonary arterial hypertension (PAH). On January 30th CS1 received FDA approval for Expanded Access also known as “Compassionate Use” after Cereno had received request to apply for CU from

There are no items matching the current filter
There are no more items matching the current filter
Back to top